{"id":19897,"date":"2024-11-25T14:04:01","date_gmt":"2024-11-25T13:04:01","guid":{"rendered":"https:\/\/synektik.com.pl\/?p=19897"},"modified":"2024-11-25T14:04:01","modified_gmt":"2024-11-25T13:04:01","slug":"record-breaking-year-and-fourth-quarter-in-the-synektik-group","status":"publish","type":"post","link":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/","title":{"rendered":"Record-breaking year and fourth quarter in the Synektik Group"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>The public radiopharmaceuticals producer and supplier of advanced medical solutions has set even more records. In the last 12 months of the 2023 financial year (October 2023 &#8211; September 2024) the Synektik Group grew sales by nearly 40% to PLN 624.8 million while earning a normalized EBITDA of PLN 146.3 million (50% growth yoy). The Group wrapped up the final quarter of the year with revenue of PLN 141.8 million (PLN 135.7 million last year) and 11% growth in normalized EBITDA coming in at PLN 35.2 million.<\/strong><\/h2>\n\n\n\n<p>The segment consisting of supplying medical equipment and IT solutions and providing maintenance and measurement services posted revenue of PLN 129.1 million in the last quarter of 2023 generating EBITDA of PLN 35.7 million (5% growth yoy). In the last 12 months of the 2023 financial year the segment\u2019s revenue totaled PLN 579.7 million (41% growth yoy net of intragroup transactions) while normalized EBITDA shot up 45% to almost PLN 144 million.<\/p>\n\n\n\n<p>The radiopharmaceuticals segment finalized the past quarter with 28% sales growth posting PLN 12.7 million (net of intragroup transactions), generating nearly PLN 4.4 million in EBITDA (30% growth). In the last 12 months of the past financial year the segment\u2019s revenue rose by almost 24% to PLN 45.1 million while EBITDA climbed 45% to PLN 16.3 million.<\/p>\n\n\n\n<p>\u201c<em>We have completed a record-breaking year in terms of financial performance that has been extraordinarily successful in the key areas of our business. In parallel, we are gathering the fruit resulting from the unwavering execution of our Group\u2019s growth strategy that places great emphasis on expanding the sales of medical equipment for therapy among other aspects while laying the foundation for Synektik SA\u2019s continued shareholder value growth. The pillar of the Group\u2019s business model is focusing on innovative medical technologies. We intend to continue investing boldly in expanding our offer to include new products that will deliver new quality in health care in Poland and more broadly across the region and the globe. We would like for our new financial year to herald further strengthening of our position on the Polish market, expansion in Central European countries and unwavering execution of strategic research and development projects headed up by the cardio marker<\/em>\u201d, remarks <strong>Cezary Kozanecki, Synektik\u2019s founder and CEO<\/strong>.<\/p>\n\n\n\n<p>The past financial year in the Synektik Group witnessed ongoing dynamic growth in recurring revenue in both segments achieved by delivering products and services as part of long-term contracts. The Group\u2019s recurring revenue skyrocketed 69% to PLN 207.4 million in the last 12 months of the 2023 financial year. The rapid development of surgical robotics in Poland, the Czech Republic and Slovakia generating demand for instruments and consumable accessories in the da Vinci robotic systems under the Group\u2019s care was a significant driver of the growth in the Group\u2019s recurring revenue. In the last four quarters in Poland, more than 11.8 thousand surgical procedures were performed in total using da Vinci systems (100% growth yoy), while more than 9.4 thousand procedures were performed in the Czech Republic and Slovakia (36% growth yoy).<\/p>\n\n\n\n<p>In the past financial year the Group delivered 27 da Vinci systems to clients in Poland, the Czech Republic and Slovakia, thereby increasing the number of robots under the Group\u2019s care. <strong>Dariusz Korecki, the Vice-President of Synektik<\/strong> highlights that the popularization of medical robotics is not slowing down, thereby opening up new business opportunities to the Synektik Group. \u201c<em>We are participating in a qualitative revolution in many areas of health care related to the implementation of robotic technologies. From year to year an ever larger community of patients in our part of the globe is being afforded the chance to take advantage of more effective therapy and faster and more effective convalescence thanks the usage of robots in surgical procedures. Not only is the number of systems operated by hospitals on the rise, the circle of highly qualified surgeons and the utilization of robots are also expanding. In our opinion, we are still in the initial phase of this qualitative transformation. As the Synektik Group we intend to continue pursuing this process by bringing more advanced solutions to the market<\/em>\u201d, remarks <strong>Dariusz Korecki<\/strong>. In recent months the Group has expanded its product offering to include Symani robotic systems for microsurgery and super microsurgery becoming their sole distributor in Poland, the Czech Republic, Slovakia, Latvia, Latvia and Estonia while tightening its partnership with the producer of the da Vinci systems by extending the cooperation agreement until at least the end of the decade and enlarging its geographic catchment area to cover the Baltic States. The Group is also the sole distributor in Poland of systems for mammography and biopsy producer by Hologic, the global leader in women\u2019s health.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\">See the financial statement <\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The public radiopharmaceuticals producer and supplier of advanced medical solutions has set even more records. In the last 12 months of the 2023 financial year (October 2023 &#8211; September 2024) the Synektik Group grew sales by nearly 40% to PLN 624.8 million while earning a normalized EBITDA of PLN 146.3 million (50% growth yoy). The [&hellip;]<\/p>\n","protected":false},"author":17,"featured_media":8090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[247,248,249],"tags":[],"class_list":["post-19897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investor-relations","category-news","category-press-releases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Record-breaking year and fourth quarter in the Synektik Group - Synektik<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Record-breaking year and fourth quarter in the Synektik Group - Synektik\" \/>\n<meta property=\"og:description\" content=\"The public radiopharmaceuticals producer and supplier of advanced medical solutions has set even more records. In the last 12 months of the 2023 financial year (October 2023 &#8211; September 2024) the Synektik Group grew sales by nearly 40% to PLN 624.8 million while earning a normalized EBITDA of PLN 146.3 million (50% growth yoy). The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Synektik\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Synektik\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T13:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"390\" \/>\n\t<meta property=\"og:image:height\" content=\"340\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jstefanska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@synektik1\" \/>\n<meta name=\"twitter:site\" content=\"@synektik1\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\"},\"author\":{\"name\":\"jstefanska\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/674e6cb0be4d783919e89d982c8f53f2\"},\"headline\":\"Record-breaking year and fourth quarter in the Synektik Group\",\"datePublished\":\"2024-11-25T13:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\"},\"wordCount\":768,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg\",\"articleSection\":[\"Investor relations\",\"News\",\"Press releases\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\",\"url\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\",\"name\":\"Record-breaking year and fourth quarter in the Synektik Group - Synektik\",\"isPartOf\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg\",\"datePublished\":\"2024-11-25T13:04:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage\",\"url\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg\",\"contentUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg\",\"width\":390,\"height\":340},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/synektik.jcd.pl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Record-breaking year and fourth quarter in the Synektik Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/synektik.jcd.pl\/#website\",\"url\":\"https:\/\/synektik.jcd.pl\/\",\"name\":\"Synektik\",\"description\":\"Grupa Synektik jest wiod\u0105cym producentem zaawansowanych produkt\u00f3w radiofarmaceutycznych oraz rozwi\u0105za\u0144 informatycznych, dostawc\u0105 us\u0142ug serwisowo-pomiarowych oraz dystrybutorem innowacyjnych urz\u0105dze\u0144 medycznych, stosowanych w diagnostyce oraz terapii w dziedzinach radiologii, onkologii, kardiologii i neurologii.\",\"publisher\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/synektik.jcd.pl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\",\"name\":\"Synektik Group\",\"url\":\"https:\/\/synektik.jcd.pl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png\",\"contentUrl\":\"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png\",\"width\":675,\"height\":675,\"caption\":\"Synektik Group\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Synektik\/\",\"https:\/\/x.com\/synektik1\",\"https:\/\/www.linkedin.com\/company\/synektik\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/674e6cb0be4d783919e89d982c8f53f2\",\"name\":\"jstefanska\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d3ba4e857dfc2b5dada99a4ae350c100?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d3ba4e857dfc2b5dada99a4ae350c100?s=96&d=mm&r=g\",\"caption\":\"jstefanska\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Record-breaking year and fourth quarter in the Synektik Group - Synektik","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Record-breaking year and fourth quarter in the Synektik Group - Synektik","og_description":"The public radiopharmaceuticals producer and supplier of advanced medical solutions has set even more records. In the last 12 months of the 2023 financial year (October 2023 &#8211; September 2024) the Synektik Group grew sales by nearly 40% to PLN 624.8 million while earning a normalized EBITDA of PLN 146.3 million (50% growth yoy). The [&hellip;]","og_url":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/","og_site_name":"Synektik","article_publisher":"https:\/\/www.facebook.com\/Synektik\/","article_published_time":"2024-11-25T13:04:01+00:00","og_image":[{"width":390,"height":340,"url":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg","type":"image\/jpeg"}],"author":"jstefanska","twitter_card":"summary_large_image","twitter_creator":"@synektik1","twitter_site":"@synektik1","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#article","isPartOf":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/"},"author":{"name":"jstefanska","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/674e6cb0be4d783919e89d982c8f53f2"},"headline":"Record-breaking year and fourth quarter in the Synektik Group","datePublished":"2024-11-25T13:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/"},"wordCount":768,"commentCount":0,"publisher":{"@id":"https:\/\/synektik.jcd.pl\/#organization"},"image":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage"},"thumbnailUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg","articleSection":["Investor relations","News","Press releases"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/","url":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/","name":"Record-breaking year and fourth quarter in the Synektik Group - Synektik","isPartOf":{"@id":"https:\/\/synektik.jcd.pl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage"},"image":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage"},"thumbnailUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg","datePublished":"2024-11-25T13:04:01+00:00","breadcrumb":{"@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#primaryimage","url":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg","contentUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/04\/CroppedFocusedImageWyIzOTAiLCIzNDAiLCI1MC01MCJd-wzrost6.jpeg","width":390,"height":340},{"@type":"BreadcrumbList","@id":"https:\/\/synektik.jcd.pl\/en\/record-breaking-year-and-fourth-quarter-in-the-synektik-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/synektik.jcd.pl\/en\/"},{"@type":"ListItem","position":2,"name":"Record-breaking year and fourth quarter in the Synektik Group"}]},{"@type":"WebSite","@id":"https:\/\/synektik.jcd.pl\/#website","url":"https:\/\/synektik.jcd.pl\/","name":"Synektik","description":"Grupa Synektik jest wiod\u0105cym producentem zaawansowanych produkt\u00f3w radiofarmaceutycznych oraz rozwi\u0105za\u0144 informatycznych, dostawc\u0105 us\u0142ug serwisowo-pomiarowych oraz dystrybutorem innowacyjnych urz\u0105dze\u0144 medycznych, stosowanych w diagnostyce oraz terapii w dziedzinach radiologii, onkologii, kardiologii i neurologii.","publisher":{"@id":"https:\/\/synektik.jcd.pl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/synektik.jcd.pl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/synektik.jcd.pl\/#organization","name":"Synektik Group","url":"https:\/\/synektik.jcd.pl\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/","url":"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png","contentUrl":"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png","width":675,"height":675,"caption":"Synektik Group"},"image":{"@id":"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Synektik\/","https:\/\/x.com\/synektik1","https:\/\/www.linkedin.com\/company\/synektik\/"]},{"@type":"Person","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/674e6cb0be4d783919e89d982c8f53f2","name":"jstefanska","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d3ba4e857dfc2b5dada99a4ae350c100?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d3ba4e857dfc2b5dada99a4ae350c100?s=96&d=mm&r=g","caption":"jstefanska"}}]}},"_links":{"self":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/19897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/comments?post=19897"}],"version-history":[{"count":1,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/19897\/revisions"}],"predecessor-version":[{"id":19898,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/19897\/revisions\/19898"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/media\/8090"}],"wp:attachment":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/media?parent=19897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/categories?post=19897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/tags?post=19897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}